Covalon Launches New "CLABSI Conscious" Campaign to Help Children Heal Without Infections - Nov 8, 2022
Covalon Launches New "CLABSI Conscious" Campaign to Help Children Heal Without Infections

Amongst a climbing Central Line Associated Blood Stream Infection ("CLABSI") rate across the United States, Covalon is releasing new digital resources focused on the role of technology to strengthen and reinforce infection prevention practices.

MISSISSAUGA, ON, Nov. 8, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV)  (OTCQX: CVALF), an advanced medical technologies company, is ramping up awareness about rising Central Line Associated Blood Stream Infection ("CLABSI") rates across the U.S. with new digital resources designed to bring the standard infection ratio for CLABSI down, specifically in pediatric patients.

Covalon is taking a stand against the significant rise in the standard infection ratio for CLABSI through a new "CLABSI Conscious" campaign geared to minimize human error, maintain safety consistency, and empower frontline healthcare teams with the technology they need to reduce CLABSIs in pediatric patients.

"The CDC has reported a 47% increase in CLABSIs in US hospitals and a 65% increase in infections in intensive care units," says Brian Pedlar, CEO of Covalon. "Sick children don't deserve a CLABSI. While healthcare providers continue to deal with unprecedented challenges, there are effective and practical solutions at our fingertips to help all patients, especially children to heal with their best chance for recovery and comfort."

Covalon's new campaign focuses on the role that CLABSI-conscious technology can play in maintaining safety consistency across healthcare sites, teams, and procedures. The list of CLABSI prevention practices at most hospitals is long, including highly specialized sterilization protocols, hand hygiene mandates, training toolkits, and more, but the role that advanced technology plays is often overlooked. CLABSI-conscious technology can help support CLABSI protocols by preventing human error, streamlining workflows, and protecting patients using innovative dual-antimicrobial infection prevention formulas like silver combined with chlorhexidine.

As part of the CLABSI Conscious campaign, Covalon:

  • Launched a brand new blog that provides resources for healthcare professionals, patients and care providers on the role technology plays in compassionate care, improving patient outcomes, and infection prevention 
  • Renewed its social media presence on LinkedIn, Twitter, Instagram, and Facebook with content that brings greater awareness to the social, emotional, and economic cost of infections, especially in vulnerable patients 
  • Is hosting an expert-led webinar on November 9 in collaboration with Paula Lamagna, RN, Education Coordinator, Vascular Access Team, at Boston Children's Hospital to address climbing CLABSI rates in pediatric patients. Webinar registration details are below.
Webinar Details

CLABSI Prevention: New Technology to Address Rising CLABIS Infection Rates in Pediatric Patients
Date: Thursday, November 10th at 1:00 pm EST, 10:00 am PST
Registration: Click here to register
Hashtag: #InfectionPrevention

"Healthcare leaders around the world are aware of the toll that frontline shortages, healthcare worker burnout, and the aftermath of the COVID-19 pandemic have taken on the provision of healthcare and patient outcomes," says Brian Pedlar. "We are ramping up our resources, outreach, partnerships, and plans to help frontline teams save time, stop stressful setbacks from happening, and ultimately save lives."

About Covalon

Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the three and nine months ended June 30, 2022, which is available on the Company's profile at www.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events or otherwise, except as required by law.

SOURCE Covalon Technologies Ltd.

For further information: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: bpedlar@covalon.com, Phone: 905.568.8400 x 233, Toll-Free: 1.877.711.6055, Website: https://covalon.com/, Twitter:@covalon